Last Updated: November 16, 2026

Investigational Drug Information for Basmisanil

« Back to Dashboard


What is the drug development status for Basmisanil?

Basmisanil is an investigational drug.

There have been 4 clinical trials for Basmisanil. The most recent clinical trial was a Phase 2 trial, which was initiated on November 30th 2016.

The most common disease conditions in clinical trials are Cognition Disorders, Stroke, and Ischemic Stroke. The leading clinical trial sponsors are Hoffmann-La Roche and [disabled in preview].

There are zero US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Basmisanil
TitleSponsorPhase
A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children With Dup15q SyndromeHoffmann-La RochePhase 2
A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic StrokeHoffmann-La RochePhase 2
A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With AntipsychoticsHoffmann-La RochePhase 2

See all Basmisanil clinical trials

Clinical Trial Summary for Basmisanil

Top disease conditions for Basmisanil
Top clinical trial sponsors for Basmisanil

See all Basmisanil clinical trials

US Patents for Basmisanil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Basmisanil ⤷  Start Trial Bisarylsulfonamides useful in the treatment of inflammation and cancer Kancera AB ⤷  Start Trial
Basmisanil ⤷  Start Trial Polycyclic compounds as lysophosphatidic acid receptor antagonists Amira Pharmaceuticals Inc ⤷  Start Trial
Basmisanil ⤷  Start Trial Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors Incyte Corp , Incyte Holdings Corp ⤷  Start Trial
Basmisanil ⤷  Start Trial Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors Novartis AG ⤷  Start Trial
Basmisanil ⤷  Start Trial Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Basmisanil

Drugname Country Document Number Estimated Expiration Related US Patent
Basmisanil Australia AU2012356738 2031-12-22 ⤷  Start Trial
Basmisanil Brazil BR112014015607 2031-12-22 ⤷  Start Trial
Basmisanil Canada CA2859586 2031-12-22 ⤷  Start Trial
Basmisanil China CN104168958 2031-12-22 ⤷  Start Trial
Basmisanil European Patent Office EP2794009 2031-12-22 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.